Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso

AIDS Research and Human Retroviruses

Volumn 23, Issue 8, 2007, Pages 955-964

  Ruelle, Jean ^a   Sanou, Mahamoudou ^b   Liu, Hsin Fu ^c,d   Vandenbroucke, Anne Thérèse ^a   Duquenne, Armelle ^a   Goubau, Patrick ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Camp de l'Unité ^*  (Burkina Faso)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

AFRICA; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEROLOGY; VIRUS LOAD; VIRUS STRAIN;

ADULT; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BURKINA FASO; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-2; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; POLYMORPHISM, GENETIC; VIRAL LOAD;

EID: 34848925709     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0034     Document Type: Article

References (44)

1. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, and Vandamme AM: Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA 2003;100:6588-6592.
2. Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, et al.: Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Tai Forest, Cote d'Ivoire: Implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 2005;79:12515-12527. Erratum in J Virol. 2006;80:4645.
3. Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, and Hahn BH: The origins of acquired immune deficiency syndrome viruses: Where and when? Philos Trans R Soc Lond B Biol Sci 2001;356:867-876.
4. Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, et al.: Genetic diversity of human immunodeficiency virus type 2: Evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994;68:7433-7447.
5. Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, et al.: Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol 1997;71:3953-3960.
6. Pieniazek D, Ellenberger D, Janini LM, Ramos AC, Nkengasong J, Sassan-Morokro M, et al.: Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 1999;15:603-608.
7. Ishikawa K, Janssens W, Banor JS, Shinno T, Piedade J, Sata T, et al.: Genetic analysis of HIV type 2 from Ghana and Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 2001;17:1661-1663.
8. Simon F, Matheron S, Tamalet C, Loussert-Ajaka I, Bartzack S, Pépin JM, et al.: Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993;7:1411-1417.
9. Kanki PJ, Travers KU, MBoup S, Hsieh CC, Marlink RG, Gueye-NDiaye A, et al.: Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-946.
10. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al.: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. 1 Science 1994;265:1587-1590.
11. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. DHHS. Revised May 4, 2006. http://aidsinfo.nih.gov/guidelines.
12. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2005. http://www.bhiva.org.uk.
13. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, Bouchez JM, et al.: Antiretroviral therapy in HIV-2-infected patients: Changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003;(Suppl. 3):S49-54.
14. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al.: CD4 cell recovery in treated HIV-2 infected adults is lower than expected: Results from the French ANRS CO5 HIV-2 cohort. AIDS 2006;20:459-462.
15. van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, et al.: Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 2003;(Suppl. 3):S55-61.
16. Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, et al.: Virological and immunolgical response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 2006;20:1455-1458.
17. Mullins C, Eisen G, Poper S, Dieng Sarr A, Sankalé JL, Berger JJ, et al.: Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin Infect Dis 2004;38:1771-1779.
18. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, and Heneine W: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and post-exposure prophylaxis. Antiviral Ther 2004;9:57-65.
19. Rodès B, Sheldon J, Toro C, Jimenez V, Alvarez A, and Soriano V: Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 2006;57:709-713.
20. Gilleece Y, Breuer J, Hawkins D, and Smith N: The British HIV association for antiretroviral treatment of HIV-2 positive individuals, 2004.
21. Pieniazek D, Rayfield M, Hu DJ, Nkengasong JN, Soriano V, Heneine W, et al.: HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 2004;18:495-502.
22. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, and Stammers DK: Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA 2002;99:14410-14415.
23. Colson P, Henry M, Tivoli N, Gallais H, Gastaut JA, Moreau J, et al.: Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol 2005;75:381-390.
24. Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, et al.: Selection of K65R mutation in HIV-2 infected patients receiving tenofovir-containing regimen. Antiviral Ther 2004;9:635-636.
25. Brandin E, Lindborg L, Gyllenstein K, Broström C, Hagberg L, Gisslen M, et al.: pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2003;7:543-550.
26. Hightower M and Kallas EG: Diagnosis, antiretroviral therapy and emergence of resistance to antiretroviral agents in HIV-2 infection: A review. Br J Infect Dis 2003;7:7-15.
27. Rodés B, Toro C, Sheldon JA, Jiménez V, Mansinho K, and Soriano V: High rate of proV47A selection in patients failing lopinavir-based HAART. AIDS 2006;20:127-129.
28. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, et al.: Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in southern France. J Clin Microb 2004;42:570-577.
29. Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, et al.: Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2 infected patients treated with protease inhibitors. J Clin Microb 2005;43:484-487.
30. Ruelle J, Kabamba Mukadi B, Schutten M, and Goubau P: Quantitative real-time PCR on Lightcycler® for the detection of human immunodeficiency virus type 2 (HIV-2). J Virol Methods 2004;17:67-74.
31. Kumar S, Tamura K, and Nei M: MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 2004;5:150-163.
32. Felsenstein, J: PHYLIP (Phylogeny Inference Package) version 3.6. Distributed by the author. Department of Genome Sciences. University of Washington, Seattle, WA, 2005.
33. Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, et al.: High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004;74: 197-201.
34. Parreira R, Monteiro F, Padua E, Piedade J, Venenno T, Paixao MT, et al.: Natural polymorphisms of HlV type 2 pol sequences from drug-naive individuals. AIDS Res Hum Retroviruses 2006;22:1178-1182.
35. Fontenot G, Johnston K, Cohen JC, Gallaher WR, Robinson J, and Luftig RB: PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. Virology 1992;190:1-10.
36. Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, et al.: Antiretroviral therapy for HIV-2 infected patients. J Infect 2001;42:126-133.
37. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al.: Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994;243:369-387.
38. Prater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, et al.: Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001;15:1493-1502.
39. Bakhanashvili M and Hizi A: Fidelity of the reverse transcriptase of human immunodeficiency virus type 2. FEBS Lett 1992;306:151-156.
40. Boyer PL, Sarafianos SG, Clark PK, Arnold E, and Hughes SH: Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PloS Pathogens 2006;2:101-111.
41. Turner D, Brenner B, and Wainberg MA: Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin Diagn Lab Immunol 2003;10: 979-981.
42. Deeks SG, Hon R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, et al.: Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005;192:1537-1544.
43. Tebit DM, Ganame J, Sathiandee K, Nagabila Y, Coulibaly B, and Krausslich HG: Diversity of HIV in rural Burkina Faso. J Acquir Immune Defic Syndr 2006;43:144-152.
44. Nam JG, Kim GJ, Baek JY, Suh SD, Kee MK, Lee JS, et al.: Molecular investigation of human immunodeficiency virus type 2 subtype A cases in South Korea. J Clin Microb 2006;44:1543-1546.